Heart failure & cardiomyopathies
Design and Baseline Characteristics of SALT-HF Trial: Hypertonic Saline Therapy in Ambulatory Heart Failure
Authors' conclusion
SALT-HF trial randomized 167 ambulatory patients with WHF and will determine whether an infusion of hypertonic saline therapy plus furosemide increases diuresis and improves decongestion compared to equivalent furosemide administration alone.
Study context
- Population
- Ambulatory patients with worsening heart failure (HF) without criteria for hospitalisation, ≥2 signs of volume overload, oral furosemide ≥ 80 mg daily and elevated natriuretic peptidesrandomised
- Participants
- 167 patients
- Comparison
- Intravenous (IV) furosemide plus hypertonic saline vs IV furosemide alone
- Primary endpoint
- Diuresis
- Follow-up
- 3 h after treatment started
Methodological detailsmulticentre, double-blind, 1:1 randomisation, 13 sites, Randomised December 2020 to March 2023
- Multicentre
- Double-blind
- 1:1 randomisation
- 13 sites
- Randomised December 2020 to March 2023
Primary result
As reported in the abstract
Baseline characteristics · baseline
- Age, median (IQR 73-87), years
- 81
- Females
- 30.5%
- EF >50%
- 82
- Charlson index, median (IQR 2-4)
- 3
- DM
- 41%, n = 69
- AF
- 80%, n = 134
- CKD
- 64%, n = 107
- NYHA III
- 69%
- Composite congestion score, mean (SD 1.7)
- 4.3
- Oedema and jugular engorgement
- 90%, n = 151
- Lung B lines on ultrasound
- 71% (n = 118)
- Inferior vena cava diameter, median (IQR 21-25), mm
- 23
- NT-proBNP, median (IQR 2508-9328), pg/mL
- 4969
- CA125, median (IQR 20-114), U/L
- 46
Original publication
Design and Baseline Characteristics of SALT-HF Trial: Hypertonic Saline Therapy in Ambulatory Heart Failure. ESC Heart Fail. Published 21 February 2024. doi:10.
Summarised from the published abstract; every number is checked against it